Abstract 468P
Background
Traditional Chinese Medicine (TCM) is effective in alleviating side-effects of radiotherapy and chemotherapy. While TCM is popular among cancer patients, their health-seeking behavior is not well described. Safety data regarding concurrent use with oncology treatment is lacking.
Methods
This is a retrospective cohort study from a tertiary oncology institute. All patients who had follow-up visits in both the TCM clinic and Oncology department of the Queen Elizabeth Hospital in Hong Kong from 2011 to 2022 were recruited.
Results
Fourteen patients were identified. Twelve (85.7%) were female, median age was 64. Nine (64.3%) of them were early-stage (I-II) cancers. Amongst these 14 patients, the distribution of cancer types was as follows: breast cancer (n=6), cervical cancer (n=3), head and neck cancer (n=2), ovarian cancer (n=2) and gastrointestinal cancer (n=1). Eight (57.4%) patients started to receive TCM advice at the same year of diagnosis, while half of them received conventional cancer treatment (chemotherapy, n=2; targeted therapy, n=1; hormone therapy, n=1) simultaneously. No CTCAE v5 Grade 3 or above adverse events were observed among patients having the concomitant use of TCM and chemotherapy. However, none of them informed the oncologist regarding the use of TCM. Patients tends to complain more symptoms to TCM practitioner than to Oncologists. The major reasons for TCM treatments were the treatment-emergent side effects (n=9), followed by the wish for reconditioning after anti-cancer treatment (n=6). Patients reported that the use of herbal medicine (H) improved insomnia (3 out of 4 pts), dizziness (n=1) and cancer pain (n=1). Moreover, the combined use of H and acupuncture showed clinical improvement in chemotherapy-induced numbness (1 out of 2 pts), pain associated with avascular necrosis (n=1), fatigue (n=1) and alopecia (n=1).
Conclusions
TCM demonstrated promising results in improving long-term treatment morbidity. Yet, most patients were not willing to disclose the use of TCM. Strengthening the communication between oncologists and patients would reduce the potential risk of herb-drug interactions.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract